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1. Introduction 
Treatment of breast cancer is one of the most complex areas in oncology. Therapeutic 
approaches of breast cancer include the treatment of local disease with surgery and 
radiotherapy or both, and systemic therapy with chemotherapy, endocrine therapy (ET), 
targeted therapy or the combinations of these. The treatment strategy is influenced by several 
factors, first of all the stage and pathologic characteristics of the disease, patient comorbid 
conditions, age, menopausal status and, last but not least, the cosmetic outcome in accordance 
with the patient’s expectations. 
For those women who desire breast conserving surgery, but it is not possible due to the 
size of the tumor or who are not suitable for surgery due to inoperable tumor status (such as 
inflammatory breast cancer or other T4 tumors), neoadjuvant systemic therapy (NST) is 
considered. Efficient NST may decrease the radicality of not only of surgery, but also that of 
radiotherapy. Another benefit of NST is the prognostic information provided on the basis of 
therapy response. A good response predicts favorable outcome, and the prognosis may 
therefore be estimated more accurately and earlier than in the adjuvant setting. Hence 
nowadays NST should be considered in all cases in which adjuvant systemic therapy is 
necessary, or if by giving that as primary intervention, any benefit may be expected [1–3]. 
The complete disappearance of any invasive cancer from the breast and lymph nodes, referred 
to as a pathological complete response (pCR), means excellent prognosis [4–6]. The Food and 
Drug Administration has proposed the use of the rate of pCR as a surrogate marker, and NST 
a strategy that could be utilized for the accelerated approval of new drugs [7]. 
In neoadjuvant setting, the same systemic therapeutic regimens can be applied as in adjuvant 
setting and the therapeutic decision is based on the immuno- and molecular-pathologic 
determination of the tumor tissue in core biopsy. Currently, examinations of the following 
biomarkers are essential in all breast cancer cases: the expression of the estrogen receptor 
(ER), progesterone receptor (PgR) by immunohistochemistry (IHC), as well as, the human 
epidermal growth factor receptor 2 (HER2) expression by IHC and/or the copy number of the 
gene assessed by the in situ hybridization (ISH) technique.  
Breast cancer cases that have at least 1% of cells staining positive for ER and/or PgR, may be 
considered hormone receptor (HR)-positive. Breast cancers are classified as HER2-positive if 
scored as 3+ by IHC or if the amplification of the HER2 gene is demonstrated by an ISH 
method [2, 8, 9]; triple-negative tumors lack the expression of HR and HER2. 
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This classification serves as a guide for oncological therapy decision. In case of triple-
negative breast cancer (TNBC) or HER2-positive cases, combined chemotherapy is the 
standard therapy alone or in the latter case in combination with anti-HER2 agents 
(trastuzumab or trastuzumab plus pertuzumab). In HR-positive tumors, while the use of ET is 
strongly recommended, the necessity of chemotherapy is not obvious in all cases.  
ER-positive and HER2-negative breast cancer is the most common subtype, 
approximately 73% of all breast carcinomas show these features. This phenotype is more 
frequent with age, and shows more favorable clinical prognosis (as compared to that of 
HER2-positive and triple-negative cases), endocrine responsiveness and less sensitivity to 
chemotherapy [5, 10, 11]. ET is strongly suggested independently of the therapeutic setting 
(adjuvant, neoadjuvant or palliative). As curative therapy, tamoxifen or the aromatase 
inhibitors (AIs) are accepted in combination with or without gonadotropin-releasing hormone 
(GnRH) agonist depending on the sex hormonal status. 
Tamoxifen was the first registered ET (1978) for the treatment of breast cancer. It is a 
selective estrogen receptor modulator, binds to the ERα as an antagonist and to ERβ as an 
agonist. ERα is responsible for many of the effects of estrogen on normal and cancerous 
breast tissue, through ligand-activated transcriptional regulation and by acting as a component 
of membrane and cytoplasmic signaling cascades [12]. Adjuvant therapy with tamoxifen 
almost halves the rate of disease recurrence and reduces the annual breast cancer death rate by 
one-third, making a significant contribution to the 25-30% decrease in breast cancer mortality 
achieved in the past two decades [13]. 
Subsequently, other new ETs have been developed that target estrogen biosynthesis, the 
aromatase inhibitors. Currently, three members of the new generation AIs are available in 
medical uses: the steroidal AI exemestane, is an irreversible inhibitor of the aromatase 
enzyme, whereas the non-steroidal AIs, letrozole and anastrozole are competitive antagonists 
of that.  
In premenopausal women, the ovaries are the primary site of estrogen production. AIs are not 
capable of blocking ovarian estrogen synthesis completely; therefore they cannot be used as 
monotherapy unless in combination with ovarian suppression therapy, such as goserelin or 
leuprorelin (GnRH agonists) providing the full blockade of estrogen synthesis [14]. 
Unlike chemotherapy, ET is not able to enhance the apoptosis of cancer cells, instead, hinders 
or decelerates cell proliferation. Consequently, for maximum therapeutic effect, their 
prolonged administration is necessary, it means five or ten years in the adjuvant setting.  
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From the first clinical use of ETs, almost 10 years have passed until their neoadjuvant 
application. At the beginning only elderly women received NET [15–17] with the aim of 
avoiding chemotherapy and its side-effect, which is poorly tolerated by this population. 
Nowadays, it is generally accepted that not all HR-positive cases need chemotherapy and the 
therapy decision should depend on tumor characteristics rather than on age. Likewise, in the 
adjuvant setting in clinically low risk cases, such as pT1a/b, grade 1, ER high, N0 and similar 
ones, chemotherapy is not indicated under any circumstances. However, for the decision 
about adjuvant therapy in patients with higher clinical risk disease, the use of a multigene test, 
such as the 21-gene RT-PCR assay (OncotypeDX®) is recommended by all international 
guidelines (National Comprehensive Cancer Network - NCCN, American Society of Clinical 
Oncology - ASCO, St. Gallen). 
OncotypeDX® provides prognosis and predicts benefit of a certain systemic therapy. In 
clinical practice, three risk groups are distinguished by the assay: in cancers with low 
recurrence score (<18), the risk of relapse is very low, and the use of exclusive endocrine 
therapy is sufficient; cancers with intermediate recurrence score (18-30) sole endocrine 
therapy or sequential chemotherapy-endocrine therapy are individually selected; cases with 
high risk recurrence score (>31) show poorer prognosis, and the addition of chemotherapy 
significantly improves outcome. In fact, the recent results of the TAILOR-x study indicate 
that below the risk score of 26, there is no benefit of adjuvant chemotherapy among small and 
node-negative HR-positive and HER2-negative cases [18]. 
In node-positive cases, the use of genetic tests in the decision about chemotherapy has a less 
clear role [5]. The Panel of 15th St. Gallen International Expert Consensus Conference (2017) 
considered the node positive status as a strong negative prognostic factor regardless of the 
gene expression signature, thus, did not universally endorse the use of gene expression 
signatures for making treatment decision on adjuvant chemotherapy in node-positive cases. 
The Panel agreed that, gene expression assays (such as the 21-gene recurrence score) are 
useful tools, but the classification based on routine histopathology is still clinically valuable, 
and should be the basis of assisting treatment decision [9]. They subcategorized HR-positive 
and HER2-negative breast cancers according to the expression of Ki67 as evaluated by IHC 
or the grade: Luminal A-like tumors are typically of low grade, strongly ER/PgR-positive, 
HER2-negative and have a low proliferative fraction while Luminal B-like tumors are ER-
positive but may have variable degrees of ER/PgR expression, are of higher grade, and have a 
higher proliferative fraction. The last ESMO guideline (2015) uses the 13th St. Gallen 
Conference classification: Luminal A (ER-positive/HER2-negative, PgR≥20%, Ki67<20%), 
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Luminal B1 (ER-positive/HER2-negative, PgR<20% or Ki67≥20%), Luminal B2 (ER-
positive/HER2-positive), HER2-positive (ER/PgR-negative and HER2-positive) and Basal-
like (triple-negative) [19]. ASCO recommends the use of the proliferation marker Ki67, to 
guide the choice of adjuvant chemotherapy with caution. 
There are limited experiences with genetic tests in neoadjuvant therapy and their use is not yet 
evidence-based for decision making. Hence the decision on NET is usually based on 
conventional pathological and clinical data, and should be offered in those cases, in which the 
best response is anticipated, mostly the Luminal A-like tumors. 
Expanding clinical experiences indicate a pCR ratio of 0-17.5% in association with the length 
of NET [20, 21]. This ratio is surprisingly low as compared to the pCR rate of around 40% in 
HR-negative cases after neoadjuvant chemotherapy [5]. Nonetheless, the long-term outcome 
is excellent in spite of residual cancer in this group of patient [22]. These experiences raise the 
question, whether pCR may be considered as a reliable end-point of treatment response in this 
therapeutic modality at all. 
In contrast, HR-negative breast cancers show less favorable outcome, and the only 
available therapy is chemotherapy (alone or in combination with anti-HER2 therapies based 
on the HER2 status). In Hungary, in accordance with the international guidelines, the most 
favorable neoadjuvant therapy regimens are anthracycline-containing (doxorubicin, 
epirubicin), platinum-containing (cisplatin, carboplatin) and taxane-containing (paclitaxel, 
docetaxel) combinations. However, there is no existing reliable biomarker to guide the 
decision about the chemotherapy regimen. The breast cancer gene-1 and -2 (BRCA1/2) genes 
are members of the homologous recombination DNA repair pathway, which is responsible for 
the error-free repair of DNA double strand breaks. The hereditary mutations of these genes 
increase the risk of cancers of the breast, ovary, pancreas or prostate. The tumors with BRCA1 
or BRCA2 mutation are considered having high sensitivity to DNA crosslinking agents such 
as platinum [23]. Although von Minckwitz et al. observed a higher ratio of pCR in the BRCA 
mutant cases than in the wild-type cases, they experienced a similar pCR ratio in the 
carboplatin arm as in the non-carboplatin arm [24]. The dysfunction of the homologous 
recombination DNA repair pathway occurs in sporadic tumors as well, which are not carrying 
BRCA1/2 mutations. The Homologous Recombination Deficiency (HRD) score is an 
unweighted sum of three independent DNA-based measures of genomic instability and 
reflects the function of the homologous recombination repair pathway. The HRD score 
seemed to be a predictor of platinum sensitivity [25], but its specificity was disproved by 
Sharma et al. [26]. According to their experience, adjuvant doxorubicin and 
12 
cyclophosphamide treatment produced equally good disease-free survival in the HRD score-
positive cases [26]. 
The mechanism of anthracycline resistance has been an important question from its first 
clinical use (1974). The cellular distribution of the anthracyclines has been extensively 
studied, first by utilizing their fluorescent properties. Most likely, these agents can enter the 
cells through simple diffusion [27], then they bind to the proteasomes and by an ATP-
dependent nuclear pore-mediated mechanism get transported into the nuclei [28]. Both 
doxorubicin and epirubicin are weak bases consequently they can accumulate in acidic 
intracellular compartments, such as the lysosomes. Several studies have reported that resistant 
cancer cells are able to accumulate significantly more anthracyclines in the cytoplasmic 
organelles, resulting in reduced nuclear drug accumulation and decreased cytotoxicity [29]. 
Nonetheless, the potential molecular regulation of the drug sequestration in acidic lysosomes 
was unclear for a long time. 
In a recently published article, the amplification of 8q22 and the accompanying 
overexpression of the lysosomal-associated transmembrane protein 4b (LAPTM4B) was 
associated with worse prognosis and worse therapy response to anthracycline-based 
chemotherapy in patients with ER-negative breast cancer [30]. 
LAPTM4B is a lysosomal membrane protein that comprises four transmembrane domains. 
The lysosome membrane-stabilizing properties of LAPTM4B is responsible for retaining the 
drug in the lysosome and decrease its nuclear translocation by sequestering it in the 
cytoplasmic compartment. Knockdown of LAPTM4B not completely but significantly 
weakened the capability of lysosomes to retain doxorubicin. The preservation of lysosome 
membrane integrity by LAPTM4B also prevents cathepsin release and the following caspase-
mediated apoptosis which was detectable after doxorubicin, but not after exposure to taxol 
[31]. Based on these results, LAPTM4B seems a potential biomarker to predict anthracycline 
sensitivity. 
In HR-negative cases, the complete disappearance of the tumor after neoadjuvant 
chemotherapy is an important surrogate end-point of favorable prognosis. Nevertheless, some 
cases with residual disease achieve long-term survival. Preclinical studies have suggested that 
cytotoxic agents may partly exert their antitumor activity by inducing immune response 
against tumor cells [32–35]. This triggered immune response can keep prolonged control over 
the residual tumor cells. Each cytotoxic drug interacts with the immune system in its own 
complex manner. Not all, but certain chemotherapeutic agents, for instance doxorubicin and 
oxaliplatin, induce immunogenic cell death. This type of apoptosis is characterized by the 
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translocation of calreticulin from inside the endoplasmic reticulum to the cell surface, where it 
provides “eat me” signals for specialized antigen-presenting cells, and in particular for 
dendritic cells [34]. Dendritic cells capture the apoptotic tumor cells and cross-present their 
major histocompatibility complex (MHC) class I molecules as antigens derived from the 
internalized dying cells for recognition by CD8 T-cells [36], thus eliciting the anticancer 
immune response [35]. In addition, as a consequence of chemotherapy (e.g. doxorubicin), 
dying tumor cells release high-mobility-group box 1 (HMGB1) protein. The interaction of 
HMGB1 with the toll-like receptor 4 (TLR4) expressed by the dendritic cells, is necessary for 
the efficient cross-presentation of antigens derived from apoptotic cancer cells [32].  
The other way doxorubicin can inhibit tumor-induced immune tolerance is the 
downregulation of the programmed death-ligand 1 (PD-L1) in tumor cells [37]. PD-L1 is one 
of the two ligands of the programmed death 1 (PD-1) receptor, a co-inhibitory molecule on T-
cells. Through the display of PD-L1, tumor cells can negatively regulate T-cell activation, and 
escape immune surveillance [38]. Basically, cyclophosphamide was known for its 
immunosuppressive nature, but the preclinical findings proved this property as dose- and 
schedule-dependent. Low-dose cyclophosphamide contributes to antitumor immunity by 
suppressing regulatory T-cell function (regulatory T-cells mediate immunosuppressive 
networks), restoring the proliferative capacity of effector T-cell and natural killer (NK) cell 
cytotoxicity. In contrast, high-dose cyclophosphamide shows immunosuppressive effects and 
works solely through cytotoxicity [38, 39]. Paclitaxel, doxorubicin and cisplatin sensitize 
tumor cells to cytotoxic T-cells by making tumor cells permeable to granzyme B (a protease 
by which cytotoxic T-cells may destroy target cells) [40].  
In addition to these direct immunomodulatory properties, the mutagenic effects of 
chemotherapies on tumor cells may also participate in antitumor immune activation.  
It is likely that, only one or a few mutations per tumor are immunodominant, and the tumors 
with a higher mutational burden have an increased likelihood of bearing a highly 
immunogenic mutation [41]. Breast carcinomas carrying about one mutation/Megabase on 
average, have a modest mutational burden, at least when compared to melanomas or lung 
adenocarcinomas in which as many as 100 mutations/Megabase may be possible [42]. 
Nevertheless, the mutation rate may be raised by chemotherapy itself thereby enhancing 
immunogenicity. These acquired mutations are often translated into altered proteins including 
novel peptide sequences, which may become neo-epitopes. These neo-epitopes are believed to 
be particularly immunogenic because they are not encoded in the normal genome of the 
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individual patient, thus reactive T-cells are not subjected to central tolerance. Recognition of 
neo-epitopes by cytotoxic T-cells may lead to immune-mediated tumor regression. 
Szikriszt et al. [43] previously experimentally classified current chemotherapy regimens as 
highly mutagenic (cisplatin), moderately mutagenic (cyclophosphamide) and marginally/non-
mutagenic (paclitaxel, doxorubicin and gemcitabine). They found that cisplatin induces 20-
fold, while cyclophosphamide therapy induces 5-fold more mutations than taxanes or 
anthracyclines. Perhaps, the different mutagenic properties may also contribute to different 
immunomodulatory effect of chemotherapies [43].  
Since neoadjuvant systemic therapy is a rational option in breast cancer serving tailored 
therapy, it is a more and more accepted and practiced treatment modality. This setting 
provides at the same time a unique opportunity to gain special observations for further 
improve the outcome.  
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2. Aims 
2.1 To evaluate the benefit of one-year neoadjuvant endocrine therapy in HR-positive and 
HER2-negative breast carcinomas, as well as, to investigate the association between the 
characteristics of the residual tumor and disease outcome in this patient population. 
2.2 To examine the LAPTM4B copy number by fluorescent in situ hybridization technique 
in breast carcinoma samples obtained before treatment and its role in therapy response 
to anthracycline-based therapy versus non-anthracycline-based treatment. We 
hypothesized, that the extra copy of LAPTM4B has a negative predictive value to 
anthracycline-containing therapy. 
2.3 To compare the effects of preoperative therapy with the taxane-anthracycline 
combination (as low mutagenic regimen) versus cyclophosphamide-based 
chemotherapy (as moderately mutagenic regimen) versus taxane-platinum 
chemotherapy (as high mutagenic regimen) on the percentage of stromal tumor 
infiltrating lymphocytes. We hypothesized that induction of a higher number of 
mutations and neo-epitopes with mutagenic chemotherapy might result in stronger 
immune reactions in the tumor microenvironment, and this could be reflected by the 
increase of lymphocytic infiltration. 
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3. Patients and methods 
3.1 Study populations 
One-year neoadjuvant endocrine therapy in breast cancer 
Forty-two patients having received neoadjuvant endocrine therapy (NET) between 
04/2005 and 01/2014 were included. Patients were eligible for NET if they had histologically 
confirmed ER-positive and PgR-positive, invasive breast cancer in stages II or III 
(UICC/AJCC TNM classification system vs. 7.0) and if imaging examinations, including 
chest X-ray, abdominal ultrasonography and bone scan, ruled out distant metastases.  
The initial local/regional tumor status and that after NET were evaluated through physical 
examination, mammography, ultrasonography and breast MRI in some cases. The initial 
tumor size was determined from the size of the mammographic abnormality, or, if there was 
no abnormality, via the MRI image. Prior to the start of NET, three tissue cylinders for 
histopathological examinations were taken from each patient with a 16 G core needle. In three 
of four patients with bilateral breast cancer, only fine needle aspiration proved the existence 
of cancer in the less advanced tumor. In potential candidates for breast conserving surgery, a 
clip (O-Twist-Marker, BIP Biomed. Instrumente & Produkte GmbH, Germany) was inserted 
into the tumor for visualization purposes before the NET. 
Treatment with letrozole (n=33, postmenopausal group), or with goserelin plus letrozole 
(n=7) or with goserelin plus tamoxifen (n=2) (premenopausal group) was planned for 1 year. 
The therapeutic response was monitored by palpation every 3 months, or with imaging if 
necessary. In the event of progression, NET was replaced by neoadjuvant chemotherapy; if 
the therapeutic effect was judged to be insufficient, letrozole was replaced by tamoxifen. 
After 1 year of NET, surgery was designed individually with regard to the post-therapy 
imaging results and the initial tumor stage. The imaging response based on mammography 
was evaluated in accordance with the World Health Organization (WHO) criteria [44]. Sole 
sentinel lymph node biopsy at the time of surgery was aimed at in cases of clinical lymph 
node negativity. If the sentinel lymph was found to be metastatic, complementary axillary 
block dissection was performed.  
On the basis of the volume of the remaining tumor in the surgical specimen, the following risk 
groups were constructed: 
Group 1: no invasive tumor (stage 0) 
Group 2: small-volume residual tumor (stages IA-IIA) 
Group 3: large-volume residual tumor (stages IIB≤) + cases with clinical progression. 
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Following surgery, post-operative radiotherapy and adjuvant systemic therapy were applied in 
accordance with the institutional guidelines.  
LAPTM4B gene copy number gain and response to anthracycline-based chemotherapy in 
hormone receptor negative breast carcinomas  
A total of 143 cases with HR-negative breast carcinoma were enrolled and were 
analyzed in two different cohorts. The study was ethically approved by the Semmelweis 
University Institutional Review Board (SE-TUKEB 120/2013). 
The first cohort included 69 core biopsies of HR-negative (64 TNBC and 5 HER2-
positive) primary breast carcinoma cases diagnosed between 2004 and 2016, who received at 
least two cycles of chemotherapy, and then underwent surgery. Patients were eligible for 
neoadjuvant therapy, if they had histologically confirmed invasive breast cancer and imaging 
examinations ruled out distant metastases.  
Fifty out of 69 patients (72.5%) were treated with anthracycline-based neoadjuvant 
chemotherapy (mainly in combination with taxane), whereas 19 patients (27.5%) represented 
the control arm receiving non-anthracycline-based (mostly platinum in combination with 
taxane) chemotherapy.  
The second cohort included 74 samples of surgically removed HR-negative breast 
carcinomas (39 TNBC, 27 HER2-positive, and 8 with unknown HER2 data). Patients in this 
cohort were treated with chemotherapy in the adjuvant setting between 1999 and 2006. Out of 
these patients, 57/74 (77.0%) received anthracycline-based therapy (22.8% in combination 
with a taxane) and 13/74 (17.6%) received non-anthracycline-based therapies (as control 
arm), mainly cyclophosphamide plus methotrexate plus 5-fluorouracyl (CMF) regimen. In 
4/74 (5.4%) cases, no treatment data were available.  
Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune 
infiltration of breast cancer 
Samples of 112 patients diagnosed with breast carcinoma and treated with pre-
operative chemotherapy in four Hungarian institutions (National Institute of Oncology, Onco-
Radiology Center of Bács-Kiskun County Teaching Hospital, Semmelweis University and 
University of Szeged) between 2005 and 2017 were selected and studied retrospectively. The 
inclusion criteria were as follows: availability of both a core biopsy and surgical tumor 
sample, known clinical and treatment data, at least 2 cycles of chemotherapy administered 
before surgery, residual tumor after pre-operative chemotherapy. All patients underwent 
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breast surgery. Of the 112 cases, 103 received chemotherapy plus surgery with curative intent, 
while 9 cases had bone metastases at the beginning of pre-operative chemotherapy. 
Based on the HR and HER2 statuses, cases were classified into four different subtypes.  
According to the type of pre-operative chemotherapy, the patients were grouped into 
platinum-based (n=28), cyclophosphamide-based (n=42) and anthracycline-based (n=42) 
groups. In platinum-based group, 21 patients were treated with carboplatin plus docetaxel or 
paclitaxel and 7 patients received cisplatin plus docetaxel or paclitaxel. In cyclophosphamide-
based group, 57.1% (n=24) received anthracycline (epirubicin (E) or doxorubicin) plus 
cyclophosphamide (C) in combination with or without 5-fluorouracil (F) followed by 
docetaxel. The other commonly used treatment regimen in this group was FEC without 
following taxane therapy in 35.7% (n=15) of the cases. In anthracycline-based group, all cases 
were treated with anthracycline plus taxane combination (of those 32/42 received epirubicin 
plus docetaxel or paclitaxel). All treatment regimens were of conventional doses and 
schedules, and selected based on valid international guidelines. 
3.2 Pathology 
The tumor histological type was defined according to the most recent WHO 
classification [45].  
IHC data were collected from the original pathology reports. Each pathology centrum used its 
own IHC protocol in accordance with the national guidelines. HR status was scored according 
to the current Hungarian Guideline [46] and the ASCO/CAP’s recommendations [47]. A case 
was considered HR-negative if the expression of ER and PgR was less than 1%. HER2 
positivity was evaluated conforming to the United Kingdom recommendations [48].  
Ki67 staining was interpreted per the recommendations of the international working group 
[49]. For the determination of the topoisomerase-II-α (TOP2A) status, nuclei of 50 tumor 
cells were counted under the microscope and the proportion of stained cells was recorded. In 
both cases, a cut-off value of 15% was applied to separate negative (≤15%) and positive 
samples (>15%) in cases who received NET. 
The degree of response to neoadjuvant therapies was categorized following Pinder et 
al. [50]. A complete pathological response (pCR) comprised either (i) no residual carcinoma 
in the breast and lymph nodes or (ii) no residual invasive tumor but ductal carcinoma in situ 
(DCIS) present in the breast and absence of any residual invasive tumor in the lymph nodes. 
A partial response to therapy (pPR) meant either (i) minimal residual disease⁄near total effect 
(e.g. <10% of tumor remaining) or (ii) evidence of response to therapy but with 10-50% of 
19 
tumor remaining or (iii) >50% of tumor cellularity remaining evident, when compared with 
the previous core biopsy sample, although some features of response to therapy being present. 
A case was consider non-responder if there was no evidence of response to therapy (pNR).  
FISH analysis of LAPTM4B copy number 
Interphase FISH analysis was used to evaluate the copy number status of LAPTM4B 
gene. The 5 µm thick formalin fixed paraffin embedded tissue (FFPE) sections were mounted 
onto Superfrost Plus positively charged slides, deparaffinized and rehydrated in distilled 
water. For antigen retrieval, sections were incubated in citric acid based antigen unmasking 
solution (Vector Laboratories, Inc. Burlingame, CA, USA) at 95 °C for 20 min. Cell lysis was 
established by incubating the sections in Triton X-100 (AppliChem GmbH, Ottoweg 4, 64291 
Darmstadt, Germany) –SSC solution at 65 °C for 30 min. Sections were then subjected to 
digestion in pepsin solution, for 12 min at 37 °C, then washed twice in SSC for 5 min. 
ZytoLight® FISH-Tissue Implementation Kit (ZytoVision GmbH, Bremerhaven, Germany) 
was used in prehybridizational steps. Sections were air dried prior to denaturation at 73 °C for 
10 min. Hybridization was performed using 4 μl of custom-made, Texas Red/FITC dual 
labelled LAPTM4B/CEN8q FISH probes (Abnova Corp., Taoyuan City, Taiwan) per slide at 
37 °C for 16-18 h in an automated hybridization chamber (ZYTOMED Systems GmbH 
Berlin, Germany). Slides were then immersed in wash buffer SSC for 30 min at 45 °C, rinsed 
in water for 10 min, air-dried. Cell nuclei were counterstained with DAPI in antifade solution 
(Vector Laboratories, Inc. Burlingame, CA, 94010, USA).  
The Leica DM RXA fluorescent microscope equipped with Leica DFC 365FX high 
performance CCD camera (Leica Microsystems GmbH, Wetzlar, Germany) and with DAPI 
long-pass, FITC and Texas Red filters was used to evaluate the hybridization results.  
Areas with well-separated cell nuclei and overall good hybridization signals were selected for 
analysis. Minimum two FISH images per case were digitally captured at 63x magnification. 
For each case, red (LAPTM4B) and green (CEN8 centromeric region) fluorescent signals were 
counted separately in at least 50 non-overlapping interphase nuclei. Based on these data the 
following parameters were calculated: average LAPTM4B copy number/cell, average CEN8q 
copy number/cell, LAPTM4B/CEN8q ratio, average LAPTM4B copy number/cell in amplified 
cell population and percentage of polysomic or amplified cells. 
TIL analysis 
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FFPE blocks of core biopsies and surgical specimens were retrieved from the four 
pathology departments (Surgical and Molecular Tumor Pathology Center, National Institute 
of Oncology and the Departments of Pathology, Bács-Kiskun County Teaching Hospital, 
Semmelweis University and University of Szeged).   
4 μm sections of representative tumor blocks were stained with hematoxylin and eosin. The 
percentage of stromal tumor infiltrating lymphocytes (StrTIL) was evaluated according to the 
recommendation of International TILs Working Group 2014 [51]. Histopathologic evaluation 
of StrTILs was performed by GCs, AMT, AV, ET and JK. Controversial cases were 
reevaluated and discussed. 
3.3 Statistical analysis 
SPSS 20.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The 
normality of the data was controlled by the Shapiro-Wilk test.  
In the first study with NET, the associations between age, initial ER, PgR, Ki67 and 
TOP2A expression as continuous variables and the three risk groups were analyzed by the 
one-way ANOVA test, whereas the menopausal status, grade, Ki67 and TOP2A as categorical 
variables were investigated by Fischer’s exact test. In order to examine the changes in the 
tumor features after NET, the paired sample t-test and the McNemar test were used for the 
continuous and categorical variables, respectively. Binary univariate logistic regression 
models were applied to examine the potential predictive role of the expression of predictive 
markers.  
Non-parametric tests: Fisher’s exact, Kruskal-Wallis, Mann-Whitney-Wilcoxon tests 
were used to compare the LAPTM4B and CEN8q copy number to the clinicopathological data 
of the primary tumors, including therapy response in the neoadjuvant cohort and distant 
metastasis formation in the adjuvant cohort as end-points. 
The association between changes in StrTIL and clinicopathological variables (type of 
pre-operative chemotherapy received, grade, immunohistochemical subtype and age) was 
calculated by the Wilcoxon-signed rank test. 
Survival analyses 
For survival analyses in each study, the Kaplan-Meier method (the log-rank test) was 
used, whereas the hazard ratios and 95% confidence intervals (CI) were calculated with the 
Cox proportional hazard regression model.  
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In the first retrospective study with NET, durations of progression-free survival (PFS) 
and overall survival (OS) times were calculated from day 1 of NET to the date of any tumor 
progression (local/regional progression, local relapse after surgery, or distant metastasis) and 
the date of death for any reason, respectively. Analyses were carried out from the aspects of 
the associations of the tumor response and the PFS with the initial tumor predictive markers, 
such as the ER, PgR and HER2 status, and the Ki67 and TOP2A protein expressions, the 
remaining tumor volume/risk group, and the differences in the tumor characteristics after the 
NET. The effects of the pathology results on PFS were analyzed with the Cox regression 
model. 
Predictive role of the LAPTM4B copy number in the adjuvant cohort was investigated 
as follows. Distant metastasis free survival (DMFS) was assessed and defined as the time 
elapsed between the first diagnosis of primary breast carcinoma to the date of appearance of 
distant metastasis. The occurrence or absence of distant metastasis was considered as an 
indirect surrogate marker for response to different chemotherapy regimens. Receiver 
operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value 
of LAPTM4B copy number used in survival tests. The Multivariate Cox regression analysis 
included the known breast carcinoma prognostic factors such as age at the initial diagnosis, 
pT, and pN status besides the LAPTM4B copy number. 
For evaluation of the association between StrTIL and survival, the DMFS was 
assessed and defined as the time interval between the first cycle of pre-operative 
chemotherapy and the date of distant relapse or death. Nine cases with bone metastases at 
baseline were excluded from the DMFS analyses. The prognostic value of StrTIL changes, 
∆StrTIL: the difference between post-StrTIL (surgical sample) and pre-StrTIL (core biopsy), 
was tested as continuous variable.  
Multivariate Cox regression analysis included the following prognostic factors: age, grade, 
HR status, type of treatment, residual tumor size and post-treatment pathological lymph node 
status. The Kaplan–Meier method was used to analyze the role of ∆StrTIL in DMFS in HR 
negative and HR positive tumor groups separately. 
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4. Results 
4.1 One-year neoadjuvant endocrine therapy in breast cancer 
Therapeutic effects 
Data of 42 patients were analyzed in the present analysis, four of them had bilateral 
breast cancers (n=46 tumors). The mean age of the cohort was 62 years (range: 36-82 years). 
33 patients (78.6%; n=36 tumors) were postmenopausal (mean age: 67 years); 9 patients 
(21.4%; n=10 tumors) were premenopausal (mean age: 45 years).  
The histologic type was invasive ductal carcinoma (n=35, 81.4%), invasive lobular carcinoma 
(n=7, 16.3%) or mucinous carcinoma (n=1, 2.3%). The patient- and tumor-related features are 
shown in Fig. 1. 
All postmenopausal patients were treated with letrozole, while among the premenopausal 
patients, 7 and 2 patients received letrozole and tamoxifen, respectively, in combination with 
goserelin. In three patients (n=4 tumors, 8.7%), the hormone therapy was changed to 
chemotherapy because of local progression. These patients were included in the survival 
analyses, but the pathological results on their surgical specimens were not used. In two 
postmenopausal patients, letrozole was replaced by tamoxifen because of the insufficient 
treatment effect after 6 or 9 months. After an overall 12 months of NET, these patients 
exhibited partial regression on clinical examination, but no relevant regression at pathological 
evaluation; mastectomy was performed in both cases. The imaging responses to NET were as 
follows: complete response (CR): 7/46 (15.2%); partial response (PR): 30/46 (65.2%); no 
change: 5/46 (10.9%); progression: 4/46 (8.7%). The following surgical interventions were 
carried out: excision n=19/42 (45.2%), mastectomy: 23/42 (54.8%); sentinel lymph node 
biopsy (SNB): 20/42 (47.6%); axillary block dissection±SNB: 22/42 (52.4%). 
According to the histopathological examination, all the 42 assessable tumors showed 
pathological response to NET. Best response, pCR was observed in 14.3% (6/42) of the 
tumors (6/46, 13.0% of all tumors). In four cases, there was residual cancer neither in the 
breast nor in the lymph nodes while in two cases, only DCIS remained (risk group 1). Most 
cases (25/46, 54.3%) belonged to risk group 2, in two patients invasive residual carcinoma 
was detected only in the lymph nodes, and in one node-negative patient, only isolated tumor 
cells were found in the breast. Finally, risk group 3 comprised 11/46 (24.0%) cases with stage 
IIB≤ residual tumor and 4/46 (8.7%) cases with clinical progression. The treatment results are 
presented in Fig. 1. 
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Figure 1 Overview of clinical events and therapy responses during neoadjuvant endocrine 
treatment 
Five of 39 patients received adjuvant chemotherapy after the surgery due to the lack of a 
significant therapeutic effect, and in one case because of the change in the phenotype to triple 
negativity. Altogether 37/39 patients continued the same endocrine therapy as that before the 
surgery. 
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Most tumors in the premenopausal group (9/10, 90.0%) were of stage II and grade 1-2, the 
expression of ER and PgR was similarly high, while that of Ki67 and TOP2A was less than in 
postmenopausal patients (Fig. 2); 2/10 tumors showed pCR. Altogether 4 premenopausal 
patients received chemotherapy, 1 patient before and 3 patients after the surgery. 
 
Figure 2 ER, PgR, Ki67 and TOP2A expression among postmenopausal and premenopausal 
cases before and after NET 
Association between tumor response to NET and tumor characteristics 
A higher initial ER expression was related to a better response to NET (Table 1). The 
likeliness of a good response to NET was increased by 7% for every 1% increase of the 
expression of ER (odds ratio: 1.070; CI: 1.007–1.138, p=0.029). No significant associations 
were detected between the initial tumor grade or the expression of PgR, Ki67 or TOP2A and 
the therapeutic response (Table 1). 
The changes in ER, PgR or HER2 expression after NET were analyzed in 32 tumors since the 
cases that progressed (n=4) or in which there was no remaining invasive tumor in the breast 
(n=8) could not be included (Fig. 1). The average expression (±SD) of ER (85.2±15.1% vs. 
65.4±32.9%; p=0.002), PgR (66.1±32.3% vs. 7.7±17.7%; p=0.001), Ki67 (17.9±12.2% vs. 
10.1±13.0%; p=0.012) and TOP2A (16.8±17.8 vs. 7.4±12.8; p=0.029) decreased significantly 
in the surgical specimens as compared with the core biopsies taken before the treatment. In 
one patient, the tumor completely lost both ER and PgR expression after NET. The HER2 
status did not display significant changes, however in a single case, although the core biopsy 
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indicated HER2 negativity, in the surgical specimen, IHC showed HER2 positivity, and FISH 
revealed the gene amplification. 
 
Table 1 Clinical and initial pathological characteristics of the three risk groups 
 
Group 1 Group 2 Group 3 
 
  
n=6  
(5 patients)   
n=25  
(23 patients) 
n=15  
(14 patients) 
p 
mean age (years, ±SD) 61.4±14.3 65.8±10.0 56.7±13.1 0.080 
     
menopausal status     
premenopausal   [n=9 patients] (n, %) 1 (11.1) 2 (22.2) 6 (66.7) 
0.040 postmenopausal [n=33 patients] (n, %) 4 (12.1) 21 (63.6) 8 (24.2) 
grade [n=43 tumors]     
I    (n, %) 2 (33.3) 1 (16.7) 3 (50.0) 
0.134 II   (n, %) 2 (6.9) 16 (55.2) 11 (37.9) 
III  (n, %) 1 (12.5) 6 (75.0) 1 (12.5) 
ER [n=43 tumors]  
   
 
percentage of stained tumor cells (mean±SD) 84.0±8.9 88.3±9.4 75.7±19.9 0.034 
Allred score (mean±SD) 7.4±0.9 7.8±0.6 7.2±1.1 0.112 
PgR [n=43 tumors] 
    
percentage of stained tumor cells (mean±SD) 48.0±34.2 68.7±29.3 52.3±40.7 0.252 
Allred score (mean±SD) 4.8±2.9 6.9±2.0 5.1±5.1 0.106 
Ki67 [n=40 tumors] 
    
percentage of stained tumor cells (mean±SD) 23.0±23.1 17.7±11.4 13.3±13.5 0.399 
≤15% (n, %) 3 (50.0) 11 (44.0) 9 (60.0) 
0.302 >15% (n, %) 2 (33.3) 12 (48.0) 3 (20.0) 
TOP2A [n=36 tumors] 
    
percentage of stained tumor cells (mean±SD) 13.0±6.7 15.6±16.4 14.1±19.7 0.939 
≤15% (n, %) 3 (50.0) 15 (60.0) 8 (53.3) 
0.712 >15% (n, %) 2 (33.3) 6 (24.0) 2 (13.3) 
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Survival after NET 
After a median follow-up time of 45.2 (range: 17.2-111.6) months, six patients 
developed distant metastases, and one patient had a second metachronous cancer in the 
opposite breast. Three patients died, two because of metastatic breast cancer, and one for a 
reason other than breast cancer. The estimated mean PFS time was 74.2 (CI: 60.4-88.0) 
months and the estimated mean OS time was 92.8 (CI: 80.0–105.7) months. The tumor 
volume remaining after NET predicted PFS levels of 85.3, 70.6 and 41.4 months in risk 
groups 1, 2 and 3, respectively (p=0.001) (Fig. 3a). The hazard ratio for PFS in groups 1 and 2 
was 0.131 (CI: 0.016-1.056, p=0.056) and 0.101 (CI: 0.022-0.468, p=0.003), respectively, as 
compared with group 3. No significant associations were detected between the pre-treatment 
or post-treatment ER, PgR and TOP2A statuses or their changes and the PFS. High expression 
(>15%) of Ki67 in the surgical specimen predicted a risk of progression (hazard ratio: 5.432, 
CI: 1.202-24.553, p=0.028). OS was not analyzed in relation with these parameters because of 
the limited number of events. 
As a result of extended follow-up (median 61.0 months, range: 17.8-136.4 months) of all 
patients, the estimated mean PFS was 93.0 months (CI: 77.0-108.9). During this period, 
metastases developed in 5 additional cases, hence overall 11/42 patients had distant 
metastases (1/5 in risk group 1; 4/23 in risk group 2; 6/14 in risk group 3); one additional 
patient had a contralateral breast cancer. Overall 13 patients died, 8 of them due to breast 
carcinoma, whereas 5 patients deceased of another cause. According to the menopausal status, 
event occurred in 3/9 premenopausal (33.3%) and 8/33 postmenopausal women (24.2%). 
Although, there was no significant difference in PFS between the premenopausal and 
postmenopausal cases (p=0.257), the estimated mean PFS was 61.5 months (CI: 38.1-84.9) 
and 101.5 months (CI: 83.6-119.4), respectively. 
Among those 34 patients who had been treated with sole endocrine therapy, 26 remained 
breast cancer-free. 
Among the patients who received additional neoadjuvant (n=3) or adjuvant (n=5) 
chemotherapy, three cases had distant metastases and in one patient developed second breast 
cancer.  
Updated survival analysis showed similar survival outcome in the 3 risk groups as earlier. 
There was no difference in PFS between risk group 1 and 2 (p=0.618), while the risk group 3 
showed the worst outcome (estimated mean PFS, CI: 113.9 months, 92.2-135.7; 97.5  months, 
83.2-111.8; 50.9 months, 24.7-77.1; p<0.001; Fig. 3b). 
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Figure 3 Progression-free survival in the three risk groups after the completion of neoadjuvant 
endocrine therapy as estimated by the Kaplan-Meier method (n=42 patients); median follow-
up time: 45.2 months, p=0.001 (a) extended median follow-up time: 61.0 months p<0.001 (b)  
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4.2 LAPTM4B gene copy number gain and response to anthracycline-based 
chemotherapy in hormone receptor negative breast carcinomas  
A total of 143 cases with HR-negative breast cancer were enrolled into two cohorts.  
The first cohort included 69 core biopsies of HR-negative (64/69 TNBC and 5/69 HER2-
positive) primary breast carcinoma cases. The mean age of patients was 50 years (range: 26-
79 years) all cases had invasive carcinoma of no special type. After neoadjuvant therapy, pCR 
was achieved in 26 cases (37.7%), pPR in 38 cases (55.1%), and pNR in 5 cases (7.2%). The 
clinicopathological data are presented in Table 2. The average LAPTM4B/CEN8q ratio was 
≥2.0 in only 6/69 (8.6%) cases with the highest ratio being 3.71. 
Considering the average LAPTM4B copy number/cell in the group of patients receiving 
anthracycline-based neoadjuvant therapy, higher average LAPTM4B gene copy number was 
observed in the pNR group compared to pCR group (4.1±1.1 vs. 2.6±0.1, p=0.029) (Figs. 4a-
b, 5a). We also compared average LAPTM4B gene copy numbers between patients who had 
no regression or who presented minimal response to anthracycline-based neoadjuvant therapy 
(>50% residual tumor remaining) (pNR+pPRiii) versus cases with pCR. Again, significantly 
higher average gene copy number was found in the group of patients with inferior response to 
anthracycline-based neoadjuvant therapy (3.3±0.3 vs. 2.6 ± 0.1, p=0.035, Fig. 5c). 
The same is true for average CEN8q being significantly higher in the pNR and pNR+pPRiii 
groups compared to pCR group (3.7±0.9 vs. 2.2±0.1, p=0.048 and 2.9±0.3 vs. 2.2±0.1, 
p=0.040 respectively). 
In the non-anthracycline-treated group of patients, we observed pNR in a single case (Fig. 
5b). Therefore, we compared LAPTM4B gene copy number between pNR+pPRiii and pCR 
groups, resulting no significant difference (p=0.360) (Fig. 5d). 
Regarding average CEN8q copies, in the non-anthracycline-treated group of patients, no 
significant diﬀerences were observed between pNR+pPRiii and pCR groups (p=0.879). 
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Table 2 Clinicopathological characteristics of patients treated with neoadjuvant 
anthracycline-based vs. non-anthracycline-based chemotherapy 
Parameter 
Anthracycline-
based group 
(n=50) 
 Non-
anthracycline-
based group 
(n=19) 
mean age (years) 50 (range: 26-79)  52 (range: 29-76) 
histological grade 
  grade 2  6 (12.0%)  1 (5.3%) 
  grade 3  44 (88.0%)  18 (94.7%) 
IHC-based molecular types 
 TNBC 46 (92.0%)  18 (94.7%) 
 HER2-positive 4 (8.0%)  1 (5.3%) 
clinical tumor stage    
  primary tumor    
    T1  1 (2.0%)  1 (5.3%) 
    T2  29 (58.0%)  13 (68.4%) 
    T3  10 (20.0%)  2 (10.5%) 
    T4  10 (20.0%)  3 (15.8%) 
  regional lymph node    
    N0 15 (30.0%)  10 (52.6%) 
    N1  13 (26.0%)  6 (31.6%) 
    N2 16 (32.0%)  3 (15.8%) 
    N3 6 (12.0%)  0 (0.0%) 
pathological response to neoadjuvant therapy 
  pCR 16 (32.0%)  10 (52.6%) 
  pPR 30 (60.0%)  8 (42.1%) 
    pPRi 6 (20%)  0 (0%) 
    pPRii 12 (40%)  1 (12.5%) 
    pPRiii 12 (40%)  7 (87.5%) 
  pNR 4 (8.0%)  1 (5.3%) 
chemotherapy regimens 
TE/TA/TAX+E/TAX+A/TAC 20 (40.0%)  - 
TEX/FEC+T 25 (50.0%)  - 
FEC 5 (10.0%)  - 
T+CDDP -  12 (63.1%) 
T+CBP/TAX+CBP -  7 (36.9%) 
neoadjuvant trastuzumab 1 (2.3%)  1 (5.9%) 
average cycle no. 5.5 (range: 2-6)  5.5 (range: 2-6) 
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Figure 4 LAPTM4B FISH images in anthracycline-treated cases. 
Normal LAPTM4B copy number in a core biopsy of case with pCR after neoadjuvant therapy 
(a) and increased average LAPTM4B gene copy number in a case without any therapy 
response after neoadjuvant therapy (b); a primary breast carcinoma case treated with adjuvant 
chemotherapy and presenting no distant organ metastasis during the follow-up period (c) and 
a primary breast carcinoma case who had increased average LAPTM4B gene copies and 
recurrence in distant organs later on (d). 
LAPTM4B gene was labelled with red, whereas chromosome 8 centromeric region was 
stained with green ﬂuorescent dye. Cell nuclei were counterstained with DAPI (blue). FISH 
photos were acquired using 63×objective.  
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Figure 5 Association between average LAPTM4B copy number and therapy response in the 
neoadjuvant cohort (a-d) and in the adjuvant cohort (e, f).  
In the neoadjuvant anthracycline-treated cases, significantly higher average LAPTM4B gene 
copy number was observed in the pNR group compared to the pCR group (p=0.029) (a). In 
the neoadjuvant non-anthracycline-treated cases, we observed pNR in a single patient (b). 
Significantly higher average LAPTM4B gene copy number was observed in the pNR+pPRiii 
group as compared to the pCR group (p=0.035) among neoadjuvant anthracycline-treated 
cases (c), whereas, in the non-anthracycline-treated cases, no significant differences were 
observed between the two groups (d). Average gene copy number was significantly higher in 
metastatic cases as compared to the non-metastatic cases in adjuvant anthracycline-treated 
cases (p=0.046) (e) and no significant diﬀerences in the non-anthracycline-treated cases (f). A 
p≤0.050 was considered statistically significant using two-sided Mann-Whitney-Wilcoxon 
exact test. AC based: anthracycline-treated; non-AC based: non-anthracycline-treated 
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In the adjuvant treated cohort, 74 FFPE samples of surgically removed HR-negative 
breast carcinomas (39/74 TNBC, 27/74 HER2-positive and 8/74 with no reliable HER2 data) 
were collected, the mean age of the patients was 52 years (32-81).  
Most cases (94.6%) had invasive carcinoma of no special type and 5.4% presented other 
histological type (n=1 invasive lobular carcinoma, n=1 carcinoma anaplasticum, n=1 
carcinoma medullare, n=1 apocrin carcinoma). During the follow-up period, distant 
metastases occurred in 30 (40.5%) cases. The clinicopathological data are presented in Table 
3.  
LAPTM4B/CEN8q ratio ≥2.0 was observed in only 4/74 (5.4%) cases. Again considering the 
average LAPTM4B gene copy number in the adjuvant anthracycline-treated patient cohort, the 
average LAPTM4B gene copy number was higher in metastatic cases, compared to the non-
metastatic ones (2.2±0.2 vs. 1.9±0.1, p=0.046, Figs. 4c-d, 5e). In patients treated with other 
than anthracycline chemotherapy, no significant differences were detected between metastatic 
vs. non-metastatic groups (Fig. 5f). 
Regarding average CEN8q copies, no significant differences were observed between 
metastatic vs. non-metastatic groups neither in anthracycline-treated nor in non-anthracycline-
treated patients.  
Comparison of the two HR-negative subtypes (HER2-positive and TNBC cases) 
showed no significant differences in the average LAPTM4B gene copy number/cell (p=0.328). 
Kaplan-Meier curve estimation based on DMFS revealed that higher LAPTM4B copy number 
was an independent predictor for DMFS in the anthracycline-treated adjuvant cohort (log-rank 
test, p=0.037). Cut-off value for poor prognosis was defined as follows: the ratio of amplified 
cell population (LAPTM4B/CEN8q≥2.0) is more than 15% and the average gene copy number 
is more than 2.5 per sample (Fig. 6). Based on these criteria, of the 22/57 patients treated with 
anthracycline-based adjuvant chemotherapy and diagnosed with distant metastases, 6/22 cases 
presented higher LAPTM4B gene copy number, whereas, in 16/22 cases, lower LAPTM4B 
gene copy number was detected. Cox regression analysis was also performed, revealing 
association between increased LAPTM4B gene copy number and worse DMFS (p=0.044).  
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Table 3 Clinicopathological characteristics of cases treated with adjuvant 
anthracycline-based vs. non-anthracycline-based chemotherapies 
Parameter 
Anthracycline- 
based group 
(n=57) 
 Non-
anthracycline- 
based group 
(n=13) 
mean age (years) 53 (range: 32-76)  50 (range: 32-81) 
histological grade    
  grade 1 2 (3.5%)  1 (7.7%) 
  grade 2  14 (24.6%)  4 (30.8%) 
  grade 3  39 (68.4%)  8 (61.5%) 
  unknown 2 (3.5%)  0 (0.0%) 
molecular type based on IHC 
  TNBC 28 (49.1%)  10 (76.9%) 
  HER2-positive 22 (38.6%)  2 (15.4%) 
  HR-negative, HER2 n.a. 7 (12.3%)  1 (7.7%) 
pathologic tumor stage    
  primary tumor    
    pT1  16 (28.1%)  1 (7.7%) 
    pT2  30 (52.6%)  7 (53.8%) 
    pT3  5 (8.8%)  2 (15.4%) 
    pT4  4 (7.0%)  1 (7.7%) 
    Unknown 2 (3.5%)   2 (15.4%) 
  regional lymph node    
    pN0 13 (22.8%)  5 (38.5%) 
    pN1  18 (31.6%)  2 (15.4%) 
    pN2 14 (24.6%)  1 (7.7%) 
    pN3 2 (3.5%)  2 (15.4%) 
    Unknown 10 (17.5%)  3 (23.0%) 
distant metastasis    
  yes 23 (40.4%)  4 (30.8%) 
  no 34 (59.6%)  9 (69.2%) 
chemotherapy regimen* 
 AC/EC 19 (33.3%)  - 
 AC+CMF/EC+CMF/FAC/FEC 25 (43.9%)  - 
  TAC/AC+T/EC+T/AC+TAX 11 (19.3%)  - 
  FEC+T /FAC+T 2 (3.5%)  - 
  Methotrexate -  2 (15.4%) 
  CMF -  9 (69.2%) 
  T -  1 (7.7%) 
CBP+T -  1 (7.7%) 
trastuzumab added 5 (8.9%)   1 (7.7%) 
*unknown n=4 
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Figure 6 Kaplan-Meier curve estimation of DMFS in the anthracycline-treated adjuvant 
cohort. 
Cut-off value for poor prognosis was defined as follows: the ratio of amplified cell 
(LAPTM4B/CEN8q≥2.0) population is more than 15% and the average gene copy number is 
more than 2.5 per sample. Based on this criterion, 6/22 cases presented higher LAPTM4B 
gene copy number, whereas, in 16/22 cases, lower LAPTM4B gene copy number was detected 
(log rank test, p value was 0.037) 
  
35 
4.3 Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the 
immune infiltration of breast cancer 
Samples from 112 individuals were available for analysis. The majority of patients 
(n=103) received neoadjuvant chemotherapy plus surgery with curative intent, while 9 women 
had bone metastases already at the beginning of the pre-operative chemotherapy. Most 
patients (86.6%, n=97) had invasive carcinoma of no special type, 42.0% (n=47) were HR-
negative and 58.0% (n=65) were HR-positive. The clinicopathological characteristics are 
reported in Table 4. At initiation of pre-operative chemotherapy the mean age of the patients 
was 55 years (range: 29-80 years). A quarter of the patients (n=28) received platinum-based 
therapy, 37.5% (n=42) received cyclophosphamide-based therapy and 37.5% (n=42) received 
anthracycline-based therapy.   
Of the 28 patients undergoing platinum-based therapy, 64.3% (n=18) were HR-negative 
(mostly triple-negative, 46.4%, n=13), while 35.7% (n=10) were HR-positive.  
Out of the 42 patients undergoing cyclophosphamide-based therapy, 23.8% (n=10) were HR-
negative and 76.2% (n=32) were HR-positive (Table 4).  
Of the 42 patients undergoing anthracycline-based therapy, 45.2% (n=19) had HR-negative 
and 54.8% (n=23) had HR-positive carcinomas.  
The majority of patients received more than four cycles of chemotherapy and the average 
cycle number was similar among the groups (Table 4). 
Out of the 22 HER2-positive cases, 68.2% (n=15) received pre-operative trastuzumab 
therapy. Trastuzumab was administered in combination with platinum-based (n=8), 
cyclophosphamide-based (n=5) or anthracycline-based (n=2) therapy (Table 4).   
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Table 4 Clinico-pathological characteristics of patients in the study on stromal tumor-infiltrating 
lymphocytes 
  
All, 
Platinum- 
based group, 
Cyclophosphamide- 
based group, 
Anthracycline- 
based group, 
  n=112 (%) n=28 (%) n=42 (%) n=42 (%) 
mean age (years; range) 55 (29-80) 53 (29-80) 55 (35-79) 57 (32-78) 
histological type (core biopsy) 
    
invasive carcinoma NST 97 (86.6) 23 (82.1) 41 (97.6) 33 (78.6) 
ILC 12 (10.7) 4 (14.3) 1 (2.4) 7 (16.6) 
other 3 (2.7) 1 (3.6) 0 (0.0) 2 (4.8) 
immunohistochemical type (core biopsy) 
    
HR-positive 65 (58.0) 10 (35.7) 32 (76.2) 23 (54.8) 
HR-positive/HER2-negative 53 (47.3) 4 (14.3) 27 (64.3) 22 (52.4) 
HR-positive/HER2-positive 12 (10.7) 6 (21.4) 5 (11.9) 1 (2.4) 
HR-negative 47 (42.0) 18 (64.3) 10 (23.8) 19 (45.2) 
HR-negative/HER2-positive 10 (8.9) 5 (17.9) 1 (2.4) 4 (9.5) 
triple-negative 37 (33.1) 13 (46.4) 9 (21.4) 15 (35.7) 
histological grade (core biopsy) 
    
grade 1 3 (2.7) 0 (0.0) 1 (2.4) 2 (4.8) 
grade 2 40 (35.7) 8 (28.6) 16 (38.1) 16 (38.1) 
grade 3 66 (58.9) 19 (67.8) 23 (54.8) 24 (57.1) 
unknown 3 (2.7) 1 (3.6) 2 (4.8) 0 (0.0) 
HR-positive  
    
grade 1 3 (2.7) 0 (0.0) 1 (2.4) 2 (4.8) 
grade 2 31 (27.7) 3 (10.7) 15 (35.7) 13 (31.0) 
grade 3 29 (25.9) 7 (25.0) 14 (33.3) 8 (19.0) 
unknown 2 (1.8) 0 (0.0) 2 (4.8) 0 (0.0) 
HR-negative  
    
grade 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
grade 2 9 (8.0) 5 (17.9) 1 (2.4) 3 (7.1) 
grade 3 37 (33.0) 12 (42.8) 9 (21.4) 16 (38.1) 
unknown 1 (0.9) 1 (3.6) 0 (0.0) 0 (0.0) 
average number of pre-operative 
chemotherapy cycles (range) 
5.3 (2-8) 5.1 (2-8) 5.1 (2-6) 5.5 (3-8) 
number of pre-operative chemotherapy 
cycles     
≤4 34 (30.4) 9 (32.1) 15 (35.7) 10 (23.8) 
>4 78 (69.6) 19 (67.9) 27 (64.3) 32 (76.2) 
chemotherapy regimens 
    
carboplatin+docetaxel or paclitaxel 21 (18.8) 21 (75.0) - - 
cisplatin+docetaxel or paclitaxel 7 (6.3) 7 (25.0) - - 
AC 2 (1.8) - 2 (4.8) - 
FEC 15 (13.4) - 15 (35.7) - 
CMF 1 (0.9) - 1 (2.4) - 
AC+docetaxel or FEC+docetaxel 24 (21.4) - 24 (57.1) - 
epirubicin+docetaxel or paclitaxel 32 (28.5) - - 32 (76.2) 
doxorubicin+docetaxel or paclitaxel 10 (8.9) - - 10 (23.8) 
pre-operative trastuzumab  15 (13.4) 8 (28.6) 5 (11.9) 2 (4.8) 
ypT 
    
<2cm 42 (37.5) 11 (39.3) 17 (40.5) 14 (33.3) 
≥2cm 69 (61.6) 16 (57.1) 25 (59.5) 28 (66.7) 
unknown 1 (0.9) 1 (3.6) 0 (0.0) 0 (0.0) 
ypN 
    
negative 31 (27.7) 9 (32.1) 11 (26.2) 11 (26.2) 
positive 75 (67.0) 18 (64.3) 29 (69.0) 28 (66.7) 
unknown 6 (5.3) 1 (3.6) 2 (4.8) 3 (7.1) 
∆StrTIL 
    
zero or positive 87 (77.7) 22 (78.6) 35 (83.3) 30 (71.4) 
negative 25 (22.3) 6 (21.4) 7 (16.7) 12 (28.6) 
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StrTIL changes before and after chemotherapy 
In the pre-treatment core biopsy samples, the median pre-StrTIL was 3.00% 
(interquartile range (IQR): 1.00-7.50) and more than 50% StrTIL (lymphocyte predominant) 
was detected in only one case. The post-StrTIL reached 50% or above in 10 cases (the pre-
operative therapy was platinum-based (n=4), FEC (n=1) or docetaxel plus epirubicin (n=5), 
(Figs. 7a-i).  
The median post-StrTIL rose significantly to 6.25% (IQR: 3.00-25.00; p<0.001) after 
treatment. Pre-StrTIL less than 1% was observed in 14 cases, while StrTIL less than 1% in the 
residual tumor occurred in only two cases. 
The increase in post-StrTIL was significant both in HR-positive (∆StrTIL positive: n=32 
(49.2%); zero: n=21 (32.3%); negative: 12 (18.5%) and HR-negative (∆StrTIL positive: n=29 
(61.7%); zero: n=5 (10.6%); negative: n=13 (27.7%) cases (p<0.001 in both groups; Table 5). 
In the subgroup of HR-positive/HER2-negative cases, the changes in StrTIL was significant 
in grade 3 cases (∆StrTIL positive: n=14 (66.7%); zero: n=3 (14.3%); negative: n=4 (19.0%); 
p=0.007) but not in grade 1-2 cases (∆StrTIL positive: n=11 (36.6%); zero: n=14 (46.7%); 
negative: n=5 (16.7%); p=0.075; Table 5).  
We did not detect any association between changes in StrTIL and other features (shown in  
Table 5). 
When analyzing the pre-StrTIL and post-StrTIL among the three treatment groups, we 
experienced significant StrTIL increase independently from the treatment applied (Tables 5-6; 
Figs. 7a, 7d, 7g). Interestingly, in the subgroup analysis, only the administration of 
cyclophosphamide resulted in a significant increase in StrTIL in HR-positive cases (∆StrTIL 
positive: n=18 (56.3%); zero: n=10 (31.2%); negative: n=4 (12.5%); p<0.001; Tables 5-6; 
Figs. 7c, 7f, 7i). 
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Figure 7 Stromal tumor-infiltrating lymphocytes (StrTIL) before and after pre-operative 
chemotherapy 
Significant StrTIL increase was observed in the three treatment groups (platinum-based: 
p=0.007 (a); cyclophosphamide-based: p<0.001 (d); anthracycline-based: p=0.047 (g). By 
analyzing separately the HR-positive (c, f, i) and HR-negative cases, only the administration 
of cyclophosphamide resulted in significant StrTIL increment in HR-positive cases (p<0.001 
(i), whereas in HR-negative cases, no strong relationship between the treatment applied and 
StrTIL changes could be proven (platinum-based: p=0.026 (b); cyclophosphamide-based: 
p=0.049 (e); anthracycline-based: p=0.063 (h). 
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Table 5 Changes in stromal tumor-infiltrating lymphocytes (StrTIL): median StrTIL levels 
before and after pre-operative chemotherapy 
    
pre-StrTIL;  post-StrTIL;  p value 
  
n 
 
median [%]; 
(IQR) 
median [%];  
(IQR) 
(Wilcoxon 
Signed-test) 
whole population 
 
112 
 
3.00 6.25 
<0.001 
    
(1.00-7.50) (3.00-25.00) 
       age <50  35 
 
3.00 5.00 
0.001 
    
(1.00-7.50) (1.00-25.00) 
 
≥50  77 
 
3.00 7.50 
<0.001 
    
(1.00-8.75) (3.00-26.25) 
       grade 1-2 43 
 
1.00 3.00 
0.011 
    
(1.00-3.00) (1.00-7.50) 
 
3 66 
 
5.00 15.00 
<0.001 
    
(1.00-11.25) (3.00-35.00) 
       HR-positive 
 
65 
 
1.00 3.00 
<0.001 
    
(1.00-3.00) (1.00-8.75) 
 
HER2-negative  53 
 
1.00 3.00 
0.002 
    
(1.00-3.00) (1.00-7.50) 
 
HER2-positive 12 
 
2.00 4.00 
0.020 
    
(1.00-3.00) (1.50-16.88) 
       HR-negative 
 
47 
 
10.00 20.00 
<0.001 
    
(3.00-20.00) (5.00-35.00) 
 
HER2-positive  10 
 
3.00 27.5 
0.012 
    
(0.88-13.1) (8.75-32.50) 
 
triple-negative 37 
 
10.00 20.00 
0.008 
    
(5.00-20.00) (5.00-35.00) 
       HR-positive/HER2-negative grade 1-2  30 
 
1.0 3.0 
0.075 
    
(1.00-3.00) (1.00-5.62) 
 
grade 3 21 
 
1.00 5.0 
0.007 
    
(1.00-6.25) (1.00-16.25) 
       platinum-based group 
 
28 
 
4.00 10.00 
0.007 
    
(1.00-13.75) (3.00-33.75) 
 
HR-positive 10 
 
2.00 3.00 
0.094 
    
(1.00-3.50) (1.00-12.50) 
 
HR-negative 18 
 
10.00 18.75 
0.026 
    
(2.50-20.00) (7.50-35.00) 
       cyclophosphamide-based group  42 
 
1.00 5.00 
<0.001 
    
(1.00-5.00) (1.00-17.50) 
 
HR-positive 32 
 
1.00 4.00 
<0.001 
    
(1.00-3.00) (1.00-14.38) 
 
HR-negative  10 
 
6.25 17.50 
0.049 
    
(2.50-20.00) (1.00-36.25) 
       anthracycline-based group 
 
42 
 
4.00 5.00 
0.047 
    
(1.00-10.00) (2.50-30.00) 
 
HR-positive  23 
 
3.00 3.00 
0.502 
    
(1.00-7.50) (1.00-7.50) 
 
HR-negative  19 
 
10.00 30.00 
0.063 
    
(3.00-25.00) (5.00-40.00) 
       cycle number ≤4  34 
 
2.00 4.00 
<0.001 
    
(1.00-5.63) (1.00-18.13) 
 
>4 78 
 
3.00 7.50 
<0.001 
    
(1.00-10.00) (3.00-28.13) 
       HER2-positive cases 
received pre-operative 
trastuzumab 
yes 15 
 
1.00 7.50 
0.006 
   
(1.00-3.00) (3.00-25.00) 
no 7 
 
5.00 30.00 
0.031 
        (1.00-7.50) (3.00-35.00) 
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Table 6 Changes of stromal tumor-infiltrating lymphocytes according to treatment 
∆StrTIL   Platinum-based 
 
Cyclophosphamide-based   Anthracycline-based 
   
all 
HR 
negative 
HR 
positive  
all 
HR 
negative 
HR 
positive  
all 
HR 
negative 
HR 
positive 
 
n (%) n (%) n (%) 
 
n (%) n (%) n (%) 
 
n (%) n (%) n (%) 
positive  
16 11 5 
 
25 7 18 
 
20 11 9 
 
(57.2) (61.1) (50.0) 
 
(59.5) (70.0) (56.3) 
 
(47.6) (57.9) (39.2) 
zero  
6 2 4 
 
10 0 10 
 
10 3 7 
 
(21.4) (11.1) (40.0) 
 
(23.8) (0.0) (31.2) 
 
(23.8) (15.8) (30.4) 
negative  
6 5 1 
 
7 3 4 
 
12 5 7 
  (21.4) (27.8) (10.0)   (16.7) (30.0) (12.5)   (28.6) (26.3) (30.4) 
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Survival analysis according to StrTIL status 
Data on DMFS was available in 103 cases. The median DMFS was 28.2 months (range: 2.6-
118.3 months). Distant metastases occurred in 31/103 (30.1%) cases. In 21/31 (67.7%) cases, 
the primary breast carcinoma was HR-negative, and in 19/31 (61.3%) cases the post-StrTIL 
was lower than 10.0% or showed a decrease in comparison with the pre-StrTIL value. As 
reported in Table 7, in univariate analyses, the HR status and the post-treatment pathological 
lymph node status were the only significant factors influencing DMFS. In the multivariate 
model changes of StrTIL showed a strong prognostic value (Table 7). The Cox analysis in 
HR-negative cases confirmed both post-StrTIL and ∆StrTIL as playing independent 
prognostic role in DMFS. Each 1% increase in post-StrTIL reduced the hazard of distant 
metastasis development by 2.6% (hazard ratio: 0.974; CI: 0.948-1.000; p=0.05) and for each 
1% ∆StrTIL increment, the risk of distant metastasis was reduced by 4.3% (hazard ratio: 
0.957; CI: 0932-0.983; p=0.001), but according to our results, the pre-StrTIL did not 
influence the DMFS. The prognostic role of StrTIL in HR-positive cases could not be proven 
(Table 8). The Kaplan-Meier analysis was carried out in HR-negative and HR-positive cases 
separately. Among HR-negative cases, increased or unchanged post-StrTIL was associated 
with better survival (Fig. 8c). 
Table 7 Factors associated with distant metastasis-free survival in the study with StrTILs 
     Univariate analysis   Multivariate analysis 
    
Hazard 
ratio 
95% CI p value 
 
Hazard 
ratio 
95% CI p value 
∆StrTIL 
 
0.976 0.950-1.004 0.091 
 
0.973 0.948-0.999 0.044 
         
age 
<50 years 1.000 
      
≥50 years 1.545 0.690-3.455 0.290 
 
0.892 0.344-2.318 0.815 
         
grade 
1-2 1.000 
      3 2.178 0.973-5.062 0.071 
 
2.236 0.841-5.943 0.107 
         
HR status 
negative 1.000 
      positive 0.237 0.111-0.505 <0.001 
 
0.169 0.072-0.398 <0.001 
         ypT <2cm 1.000 
      
 
≥2cm 2.107 0.964-4.602 0.062 
 
3.854 1.520-9.775 0.004 
         ypN negative 1.000 
1.562-17.147 
     
 
positive 
1.644 0.007 
 
6.984 
2.011-
24.261 0.002 
         pre-operative 
chemotherapy 
anthracycline-based  1.000 
      
platinum-based 0.737 0.297-1.830 0.511  0.741 0.269-2.044 0.563 
cyclophosphamide-
based 
0.642 0.284-1.451 0.287  0.961 0.388-2.379 0.931 
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Figure 8 Kaplan-Meier 
curves of survival analyses 
By analyzing the whole 
study cohort no significant 
correlation was detected 
between StrTIL and 
DMFS; p=0.161 (a). The 
same result was observed 
in HR-positive cases too; 
p=0.339 (b).   
In HR-negative cases the 
estimated median DMFS 
was significantly higher, if 
the ∆StrTIL was zero or 
positive (48.0 months; 
standard error: 8.7) 
compared to the cases 
where ∆StrTIL was 
negative (19.4 months; 
standard error: 2.4) (c).  
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Table 8. Prognostic value of pre-operative StrTIL, post-operative StrTIL and ∆StrTIL 
  HR-negative cases   HR-positive cases 
  
Hazard 
ratio 
95% CI 
p 
value  
Hazard 
ratio 
95% CI 
p 
value 
pre-StrTIL 1.022 0.997-1.049 0.088 
 
1.028 0.872-1.212 0.745 
post-StrTIL 0.974 0.948-1.000 0.050 
 
1.009 0.980-1.040 0.545 
∆StrTIL 0.957 0.932-0.983 0.001   1.010 0.978-1.044 0.546 
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5. Discussion 
Neoadjuvant endocrine therapy (NET) continued for one year resulted in pCR in 13.0% 
of the cases, two-thirds showed a significant regression and <10% presented a progression. 
De novo hormone resistance was revealed in five cases: one of them in which the tumor 
completely lost both ER and PgR expression and the other case in which the tumor has 
become HER2-positive after one-year of NET, as well as, three cases showed clinical 
progression during NET. One of the advantages of the neoadjuvant approach is that the 
benefits of the systemic therapy and thus the prognosis may be assessed in vivo. The potential 
therapy resistance could be revealed sooner than in adjuvant therapy. 
The achievement of pCR is a predictor of excellent outcome after neoadjuvant chemotherapy, 
this also seems true for the subgroup of hormone-sensitive breast cancers after NET [5]. 
Although, the rate of pCR clearly increases as the NET period is extended, the rate of pCR is 
a rare event after NET [20, 21, 52, 53] compared to chemotherapy [5]. The first clinical trials 
with 3 months or shorter duration of NET published 0-3% pCR rates [21]. Hojo et al. found 
only a single case with pCR among 25 postmenopausal patients treated with exemestane for 6 
months [20]. Allevi et al. [21] systematically treated three cohorts of 40 patients each with 
letrozole as NET for 4, 8 and 12 months, the rates of pCR in the 3 groups were 2.5, 5.0 and 
17.5% (p<0.04), respectively. We experienced similar rate of pCR (13.0%) after one year of 
NET. Concerning the optimal duration of NET, when our article was published, the last 13th 
St. Gallen International Expert Consensus [54] recommended that NET should be continued 
until maximal response, while the next Consensus meeting in 2015 changed it to either 4-8 
months or maximal response [55]. The optimum length of NET has not yet been exactly 
established, but currently all guidelines suggest surgery, when progression is experienced [2]. 
Though pCR after NET predicts excellent survival, the lack of complete response did not 
necessarily imply poor prognosis in this therapeutic approach. In our analysis with limited 
follow-up time, we experienced that the 82.6% (19/23) of patients in risk group 2 (stage IA-
IIA residual cancer) were tumor progression-free. Furthermore, their estimated mean PFS was 
more than 8 years (97.5 months) similarly to the risk group 1. In contrast, the heavy post-
treatment lymph node involvements (ypN2 or worse) was associated with poor prognosis.  
To predict outcome, different approaches have been implemented. A change in Ki67 seems to 
be an early indicator of response, and may be utilized with this aim as soon as after 2 weeks 
of endocrine therapy [56]. Indeed, the study by Allevi et al. indicated that a decrease in Ki67 
expression is manifested in the early phase of the treatment, and the expression does not 
45 
decline further on if the administration of letrozole is prolonged for 4, 8 or 12 months, despite 
the seemingly time-dependent tumor regression [21]. DeCensi et al. observed that Ki67 was a 
good predictor of the prognosis after short-term NET, with a 5.5-times higher risk of death in 
cases with a post-treatment Ki67≥20% [57]. The molecular background is that ET does not 
enhance the apoptosis of cancer cells, instead, hinders or decelerates cell proliferation. Ellis et 
al. on the basis of the long follow-up data of the P024 neoadjuvant endocrine trial developed a 
prognostic index (“preoperative endocrine prognostic index, PEPI”) incorporating post-
therapy tumor size, nodal status, grade, ER, Ki67 and the response to therapy [58]. The PEPI 
was validated in the independent IMPACT trial [59]. In good agreement with these findings, 
we found that the remaining cancer burden and post-treatment Ki67 were strong predictors of 
PFS. 
The identification of endocrine sensitive tumors used to be difficult a couple of years earlier. 
Our results, in agreement with the data of Ellis et al. [58, 60] and Toi et al. [61] point to the 
fact that the most significant predictor of the response is the initial expression of ER. 
Although the high tumor grade and high Ki67 expression may be indicators of hormone 
resistance, these markers do not exclude a good effect of hormone therapy. Currently, a more 
sophisticated method for the prediction of hormone sensitivity is gene expression profiling 
being widely available for adjuvant treatment decision in node negative cases. Although there 
are promising results with multigene tests in 1 to 3 positive lymph node cases and 
neoadjuvant cases, but the evidence is still lacking for the recommendation of routine use [2, 
8, 9, 62].  
Few published data are available on NET in premenopausal patients. In the GEICAM/2006-
03 study, the premenopausal patients were randomized to neoadjuvant chemotherapy versus 
exemestane therapy combined with goserelin [63]. While the treatment results were 
equivalent in the postmenopausal group, significantly more responses were observed in the 
chemotherapy arm than in the NET arm among the premenopausal patients (probably due to 
the lack of patient selection). Most of the previously reported NET studies were performed 
with aromatase inhibitors, but conflicting data recently appeared relating to their adjuvant use 
in premenopausal patients [64, 65]. According to our result, excellent therapy response can be 
achieved in premenopausal cases, however, the investigation of further biomarkers might be 
important in these cases, for instance BRCA mutation status. Nowadays, the role of young 
age, per se, as an indication for chemotherapy is less strongly endorsed given the growing 
appreciation for tumor biology as the determinant of outcome and the potential role for 
ovarian suppression [2, 9]. 
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The investigation of LAPTM4B copy number by FISH in HR-negative cases showed 
an association of extra copy number and worse outcome in breast cancer treated with 
anthracycline-based neoadjuvant chemotherapy.     
The patients who were resistant to neoadjuvant anthracycline-based therapy or responded to it 
but the tumor reduction was less than 50%, had significantly higher average LAPTM4B copy 
number/cell, than patients with higher tumor regression or pCR. In the adjuvant 
anthracycline-based treated cohort, the average gene copy number was higher where distant 
metastases were diagnosed during the follow-up period compared to the non-metastatic ones 
and patient with elevated LAPTM4B had worse DMFS.  
The existence of the mammalian lysosomal-associated protein transmembrane family and its 
role in multidrug resistance have been known since the 1990s [66–68]. LAPTM4A was the 
first member and two others the LAPTM4B and LAPTM5 have been described until now [69, 
70]. In the last few years, LAPTM4B received special attention and was widely investigated 
after that its overexpression was shown to be correlated with poor prognosis in several 
cancers [71, 72]. Kasper et al. [73] by analyzing different tumor types found that LAPTM4B 
was upregulated in 88% (23/26) of lung carcinomas, in 67% (18/27) of colon carcinomas, and 
in the majority of endometrial (30/44), breast (27/53) and ovarian (11/16) carcinomas. 
The LAPTM4B gene is located in chromosome 8q22 and encodes two protein isoforms, 
LAPTM4B-35 and LAPTM4B-24, with molecular weights of 35 kDa and 24 kDa, 
respectively [74]. Mostly the 35-kDa isoform of LAPTM4B is overexpressed in numerous 
tumor types. In the last few years several putative oncogenic functions of LAPTM4B were 
identified. This transmembrane protein promotes cell survival, tumorigeneses, increases cell 
proliferation and drug resistance.   
Li et al. found that the knockdown of LAPTM4B in MDA-MB-231 and BT549 cell lines leads 
to elevated nuclear localization of doxorubicin [30], thereby proving the lysosome membrane 
stabilizing properties of LAPTM4B, which is responsible for retaining and decrease nuclear 
localization of anthracycline by sequestering in cytoplasmic compartment. They observed also 
that elevated level of LAPTM4B and YWHAZ (another gene localized on 8q22) mRNAs was 
associated with shorter DMFS in women treated with adjuvant anthracycline chemotherapy, 
but in accordance with our findings, no association could be demonstrated between 
LAPTM4B alterations and treatment response in the non-anthracycline-treated cases. In 
another study, Li et al. demonstrated that LAPTM4B is required for lysosome homeostasis, 
acidification and function. By limiting lysosome-mediated cell death and promoting 
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autophagy the protein has a significant effect on cancer cell survival, including greater 
resistance to nutrient deprivation, hypoxia or doxorubicin-induced genotoxic stress [31]. 
A different study found that the interaction of the LAPTM4B-35 isoform with multidrug 
resistance protein-1 could result in increased drug efflux. In addition, LAPTM4B-35 promotes 
anti-apoptosis by the interaction of the PI3K/AKT signaling pathway [75]. Although more 
and more new LAPTM4B mechanisms of action have been described, several unanswered 
questions have still remained [76–78]. 
The prognostic value of higher average CEN8q or chromosome 8 polysomy in breast 
carcinomas is not clear. We have found significantly higher average CEN8q copy number in 
the group of patients with inferior response to anthracycline-based neoadjuvant therapy. Anna 
Batistatou et al. have found that polysomy-8 was present in 39% of HER2-positive and 30.2% 
of HER2-negative tumors. They also showed that the MYC gene amplification in the presence 
of chromosome 8 instability has distinct effects on patient outcome compared with MYC 
amplification with intact CEN8 [79]. We have analyzed the CEN8q and LAPTM4B copy 
numbers among HER2-positive and TNBC samples, but no difference was found. However, 
further analysis may be needed using higher number of cases. 
By investigating the StrTIL before and after different mutagenic chemotherapy 
regimens, we observed similar TIL elevation in the three treatment groups. There are several 
possible explanations for this lack of difference. Although we used a classification of 
chemotherapy mutagenicity based on study performed in cell lines by Szikriszt et al. [43], 
currently there are no reliable measures of mutagenic capacity of these agents in human tumor 
samples. Hence we may not be sure that the difference seen in cell lines also holds for human 
tumors in vivo. It is also possible that the higher mutagenicity of a given agent, e.g. cisplatin, 
is compensated by another mechanism, such as the downregulation of the MHC [80]. While 
this is possible, it should be noted that platinum treatment was reported to induce the 
expression of the human leukocyte antigen in breast cancer [81]. Finally, it was suggested that 
in breast cancer, the main increase in therapeutic TIL response is driven by the gamma delta 
lymphocytes and not by the alpha beta lymphocytes, notably the former mechanism is 
typically not induced by neo-epitopes [82].  
Several previous studies have evaluated the clinical importance of TILs in breast cancer. 
Distribution of TIL is variable among breast cancer subtypes, higher TIL involvement was 
observed in TNBC and HER2-positive cases than in the ER-positive/HER2-negative 
subgroup as the incidence of lymphocyte predominant cases was also significantly less 
frequent [83]. The prognostic and predictive importance of baseline TILs at the diagnosis is 
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not a new concept in triple-negative or HER2-positive breast cancers. Denkert et al. 
investigated core biopsies from two neoadjuvant anthracycline/taxane-based studies with the 
result that the percentage of TIL was a significant independent parameter for pCR in both 
cohorts, independently from the subtype of the breast cancer; lymphocyte-predominant breast 
cancer responded, with pCR rates of 40% and 42% [84]. Loi et al. in node-positive, ER-
negative/HER2-negative adjuvant anthracycline-treated breast cancer cases demonstrated that 
increasing lymphocytic infiltration was associated with excellent prognosis, and also that in 
HER2-positive breast cancer, an association exists between increasing lymphocytic 
infiltration and the magnitude of benefit of the chemotherapy regimens. Similarly to our 
results, they did not find significant prognostic association in the ER-positive/HER2-negative 
population, even if the luminal A and B subgroups as defined by Ki67 of 14% was 
investigated separately [83].  
Lymphocyte predominant (or high-TIL) tumors is the term for tumors that contain more 
lymphocytes than carcinoma cells, the threshold is >50.0-60.0%; overall, the occurrence of 
TIL-rich cases is infrequent ~10% [51]. First Dieci et al. described that the chemotherapy-
resulted high level of TIL in residual disease is a strong favorable prognostic factor in TNBC 
[85]. The correlation between post-treatment levels of TIL or ΔTIL and clinical outcome is 
less investigated. To our best knowledge, the only article about the prognostic role of the 
change in StrTIL levels between the pre- and post-treatment samples, as we did, is published 
recently by Pelekanou et al. [86]. In that study, 58 patients were involved who received 
neoadjuvant chemotherapy regardless of the HR status or used therapy regimen. They also 
found that increase in TIL count was associated with better relapse-free survival. 
Interestingly, 79.3% of their investigated cases were HR-positive. High post-treatment TIL 
levels were associated with better outcome in some studies [85, 87–89] whereas others did not 
find similar associations [90, 91]. Here we are confirming the observation that the increase of 
TIL ratio in the residual disease as a surrogate measure of anti-tumor immune activation may 
in fact reflect significant therapeutic benefit. 
Currently, the most intensively developing and the most extensively investigated field in 
oncology is immuno-oncology. Immune checkpoint inhibitors are promising agents that are 
capable to block T-cell inactivation. There are many ongoing clinical trials with PD-1 
inhibitors (pembrolizumab,) and PD-L1 inhibitors (durvalumab, atezolizumab, avelumab) in 
breast cancer. TIL status could serve as a predictive biomarker for immunotherapy with 
checkpoint inhibitors [92]. However, the clinical usefulness of chemotherapy-induced TIL in 
decision making about immunotherapy has been so far unclear.  
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6. Conclusions 
6.1 One year NET results in a pCR rate of about 13% among HR-positive breast cancers. 
The response to NET is related to the expression of ER in the pre-therapy specimen 
while outcome after NET is related to the post-therapy tumor stage and Ki67 
expression. The cases with stage IIB≤ residual tumor or Ki67 >15% have the worst 
PFS.  
Long duration NET is effective and safe in cases of hormone sensitive breast cancer. 
6.2 Analyzing LAPTM4B copy number may support future treatment decision and the use 
of alternative treatment modalities without anthracyclines should be considered for 
those patients whose cancer harbors extra copies of LAPTM4B. 
6.3 By comparing the effects of different mutagenic pre-operative chemotherapy regimens 
on the percentage of stromal tumor infiltrating lymphocytes resulted in no significant 
differences. Further investigations are warranted to clarify the mutagenicity of various 
chemotherapy agents and their role in induction of antitumor immune response. Post-
StrTIL status and the change of StrTIL after neoadjuvant chemotherapy may be used as 
new prognostic factors in HR-negative breast cancer. 
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